Physician profile
Christopher M Lee
NPI 1003814518
$1,650.57
in general payments reported to CMS, 2019-2025
19 companies · $42.20 in 2025
The $42.20 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $241 · 2020: $72.73 · 2021: $226 · 2022: $353 · 2023: $372 · 2024: $345 · 2025: $42.20.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $759.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $758.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $357.02 | 2022-2024 | Farxiga |
| Novo Nordisk INC | $228.11 | 2020-2024 | Ozempic, Rybelsus |
| Lilly USA, LLC | $173.23 | 2020-2025 | Mounjaro, Trulicity, Jardiance |
| Esperion Therapeutics, INC. | $135.54 | 2021 | |
| Amarin Pharma, INC. | $115.03 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $113.38 | 2023-2025 | Jardiance |
| Valeritas, INC. | $90.00 | 2019 | |
| Merck Sharp & Dohme LLC | $79.02 | 2019-2023 | Verquvo, Steglatro, Steglujan |
| Bayer Healthcare Pharmaceuticals INC. | $74.59 | 2022-2024 | |
| Astellas Pharma US INC | $65.83 | 2019 | |
| Novartis Pharmaceuticals Corporation | $45.86 | 2022 | |
| Abbvie INC. | $39.81 | 2021-2023 | |
| Harrow Eye, LLC | $29.01 | 2024 | Vevye |
| Sanofi-Aventis U.S. LLC | $19.36 | 2020 | |
| Abbott Laboratories | $18.46 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $18.26 | 2020 | |
| Glaxosmithkline, LLC. | $17.15 | 2024 | Trelegy Ellipta, Arexvy |
| Hikma Pharmaceuticals USA | $15.98 | 2019 | |
| Nestle Healthcare Nutrition INC. | $14.93 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.